In September 2023, the FDA issued an EUA for an updated Moderna COVID-19 mRNA vaccine for use in children aged 6 months through 11 years of age to target the Omicron variant XBB.1.5.
The FDA originally issued an EUA to Moderna in June 2022 for an mRNA COVID-19 vaccine containing the original SARS-CoV-2 virus for use in children ages 6 months through 11 years of age. In October 2022, the FDA authorized use of a Moderna bivalent COVID-19 vaccine containing the original SARS-CoV-2 variant and the Omicron BA.4/BA.5 variant in children 6 through 11 years and in infants and children aged 6 months through five years in December 2022. These previously authorized vaccine formulations are no longer available for use in the U.S.
According to the Fact Sheet provided by the FDA, each 0.25mL dose of Moderna COVID-19 mRNA vaccine contains 25 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 Omicron variant lineage XBB.1.5.
Additional ingredients contained in the vaccine include 21.8 mg sucrose, 0.13 mg tromethamine, 0.62 mg tromethamine hydrochloride, 0.011 mg acetic acid, 0.049 mg sodium acetate trihydrate, and a total lipid content of 0.5 mg (SM-102, polyethylene glycol [PEG 2000 dimyristoyl glycerol [DMG, cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC). The vaccine does not contain a preservative and the vaccine vial stopper does not contain natural latex rubber.
Children aged six months through four years are recommended to receive at least 2 doses of Moderna mRNA COVID-19 vaccine. The number of recommended doses of the authorized 25mcg Moderna COVID-19 vaccine targeting Omicron variant XBB.1.5 will depend on previously authorized doses of COVID-19 vaccine. Children aged five through 11 years are recommended to receive one dose of the 2023-2024 Moderna COVID-19 vaccine, at least two months after receipt of a previous COVID-19 dose.
There is no data on the safety or effectiveness of administering the Moderna COVID-19 vaccine with any other vaccine.
Moderna COVID-19 vaccine has not been studied for its potential to cause cancer, genotoxicity or male infertility.
On September 12, 2023, the CDC’s ACIP voted to approve use of the 25mcg dose of the 2023-2024 Moderna COVID-19 mRNA vaccine targeting the Omicron variant XBB.1.5 in all children aged 6 months through 11 years.